The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
HER2 and Responsiveness of Breast Cancer to Adjuvant Chemotherapy
Open accessAbstract
BACKGROUND: Amplification of the human epidermal growth factor receptor type 2 (HER2, also called HER2/neu) gene and overexpression of its product in breast-cancer cells may be associated with responsiveness to anthracycline-containing chemotherapy regimens. METHODS: In the randomized, controlled Mammary.5 trial, we studied 639 formalin-fixed paraffin-embedded specimens obtained from 710 premenopausal women with node-positive breast cancer who had received either cyclophosphamide, epirubicin, and fluorouracil (CEF) or cyclophosphamide, methotrexate, and fluorouracil (CMF) as adjuvant chemotherapy. HER2 amplification or overexpression was evaluated with the use of fluorescence in situ hybridization, immunohistochemical analysis, and polymerase-chain-reaction analysis. RESULTS: Amplification of HER2 was associated with a poor prognosis regardless of the type of treatment. In patients whose tumors showed amplification of HER2, CEF was superior to CMF when assessed on the basis of relapse-free survival (hazard ratio, 0.52; 95 percent confidence interval, 0.34 to 0.80; P=0.003) and overall survival (hazard ratio, 0.65; 95 percent confidence interval, 0.42 to 1.02; P=0.06). For women whose tumors lacked amplification of HER2, CEF did not improve relapse-free survival (hazard ratio for relapse, 0.91; 95 percent confidence interval, 0.71 to 1.18; P=0.49) or overall survival (hazard ratio for death, 1.06; 95 percent confidence interval, 0.83 to 1.44; P=0.68). The adjusted hazard ratio for the interaction between treatment and HER2 amplification was 1.96 for relapse-free survival (95 percent confidence interval, 1.15 to 3.36; P=0.01) and 2.04 for overall survival (95 percent confidence interval, 1.14 to 3.65; P=0.02). CONCLUSIONS: Amplification of HER2 in breast-cancer cells is associated with clinical responsiveness to anthracycline-containing chemotherapy. (cancer.gov number, NCI-V90-0027.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500
Vogel, C. L., Cobleigh, M. A., Tripathy, D., Gutheil, J. C., Harris, L. N., Fehrenbacher, L., Slamon, D. J., Murphy, M., Novotny, W. F., Burchmore, M., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.20.3.719 · Cited by 1,860
Gusterson, B. A., Gelber, R. D., Goldhirsch, A., Price, K. N., Säve-Söderborgh, J., Anbazhagan, R., Styles, J., Rudenstam, C. M., Golouh, R., & Reed, R. (1992) · Journal of Clinical Oncology · doi:10.1200/jco.1992.10.7.1049 · Cited by 838
Allred, D. C., Clark, G. M., Elledge, R., Fuqua, S. A. W., Brown, R. W., Chamness, G. C., Osborne, C. K., & McGuire, W. L. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.3.200 · Cited by 772
Fisher, B., Brown, A. M., Dimitrov, N. V., Poisson, R., Redmond, C., Margolese, R. G., Bowman, D., Wolmark, N., Wickerham, D. L., & Kardinal, C. G. (1990) · Journal of Clinical Oncology · doi:10.1200/jco.1990.8.9.1483 · Cited by 620
Levine, M. N., Bramwell, V. H., Pritchard, K. I., Norris, B. D., Shepherd, L. E., Abu-Zahra, H., Findlay, B., Warr, D., Bowman, D., Myles, J., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.8.2651 · Cited by 617
Self-citationerbB-2, p53, and Efficacy of Adjuvant Therapy in Lymph Node-Positive Breast Cancer
Thor, A. D., Berry, D. A., Budman, D. R., Muss, H. B., Kute, T., Henderson, I. C., Barcos, M., Cirrincione, C., Edgerton, S., Allred, C., et al. (1998) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/90.18.1346 · Cited by 612
Dose and Dose Intensity of Adjuvant Chemotherapy for Stage II, Node-Positive Breast Carcinoma
Wood, W. C., Budman, D. R., Korzun, A. H., Cooper, M. R., Younger, J., Hart, R. D., Moore, A., Ellerton, J. A., Norton, L., Ferree, C. R., et al. (1994) · New England Journal of Medicine · doi:10.1056/nejm199405053301801 · Cited by 577
Dose and Dose Intensity of Adjuvant Chemotherapy for Stage II, Node-Positive Breast Carcinoma
(1994) · New England Journal of Medicine · doi:10.1056/nejm199407143310226 · Cited by 556
A One-Way Components of Variance Model for Categorical Data
Landis, J. R., & Koch, G. G. (1977) · Biometrics · doi:10.2307/2529465 · Cited by 478
Allred, D. C., Clark, G. M., Tandon, A. K., Molina, R., Tormey, D. C., Osborne, C. K., Gilchrist, K. W., Mansour, E. G., Abeloff, M., & Eudey, L. (1992) · Journal of Clinical Oncology · doi:10.1200/jco.1992.10.4.599 · Cited by 456
Efficacy of Adjuvant Chemotherapy in High-Risk Node-Negative Breast Cancer
Mansour, E. G., Gray, R., Shatila, A. H., Osborne, C. K., Tormey, D. C., Gilchrist, K. W., Cooper, M. R., & Falkson, G. (1989) · New England Journal of Medicine · doi:10.1056/nejm198902233200803 · Cited by 352
Pegram, M. D., Finn, R. S., Arzoo, K., Beryt, M., Pietras, R. J., & Slamon, D. J. (1997) · Oncogene · doi:10.1038/sj.onc.1201222 · Cited by 332
Knoop, A. S., Knudsen, H., Balslev, E., Rasmussen, B. B., Overgaard, J., Nielsen, K. V., Schonau, A., Gunnarsdóttir, K., Olsen, K. E., Mouridsen, H., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.11.007 · Cited by 320
Press, M. F., Sauter, G., Bernstein, L., Villalobos, I. E., Mirlacher, M., Zhou, J.-Y., Wardeh, R., Li, Y.-T., Guzman, R., Ma, Y., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0636 · Cited by 311
Paik, S. (2000) · Journal of the National Cancer Institute · doi:10.1093/jnci/92.24.1991 · Cited by 304
Leo, A. D., Gancberg, D., Larsimont, D., Tanner, M., Järvinen, T. A. H., Rouas, G., Dolci, S., Leroy, J.-Y., Paesmans, M., Isola, J. J., et al. (2002) · PubMed · Cited by 267
High-Dose Chemotherapy with Hematopoietic Stem-Cell Rescue for High-Risk Breast Cancer
Rodenhuis, S., Bontenbal, M., Beex, L. V. A. M., Wagstaff, J., Richel, D. J., Nooij, M. A., Voest, E. E., Hupperets, P., van Tinteren, H., Peterse, H. L., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022794 · Cited by 258
Levine, M. N., Pritchard, K. I., Bramwell, V. H. C., Shepherd, L. E., Tu, D., & Paul, N. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.09.423 · Cited by 220
Self-citationCharacterization of topoisomerase II alpha gene amplification and deletion in breast cancer.
Järvinen, T. A. H., Tanner, M., Barlund, M. T., Borg, Å., & Isola, J. J. (1999) · PubMed · Cited by 188
Clahsen, P. C., van de Velde, C. J., Duval, C., Pallud, C., Mandard, A. M., Delobelle-Deroide, A., van den Broek, L., Sahmoud, T. M., & van de Vijver, M. J. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.2.470 · Cited by 171
Leo, A. D., Larsimont, D., Gancberg, D., Järvinen, T. A. H., Beauduin, M., Vindevoghel, A., Michel, J., Focan, C., Ries, F., Gobert, P., et al. (2001) · Annals of Oncology · doi:10.1023/a:1011669223035 · Cited by 107
HER2 Overexpression and Doxorubicin in Adjuvant Chemotherapy for Resectable Breast Cancer
Moliterni, A., Ménard, S., Valagussa, P., Biganzoli, E. M., Boracchi, P., Balsari, A., Casalini, P., Tomasic, G., Marubini, E., Pilotti, S., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.04.021 · Cited by 99
O’Malley, F. P., Parkes, R. K., Latta, E. K., et al. (2001) · American Journal of Clinical Pathology · doi:10.1309/vp4w-5c55-7m09-6tx3 · Cited by 67
Self-citationLevine, M. N., Bramwell, V. H. C., Pritchard, K. I., Perrault, D. J., Findlay, B., Abu-Zahra, H., Warr, D. G., Arnold, A., & Skillings, J. R. (1993) · European Journal of Cancer · doi:10.1016/0959-8049(93)90573-x · Cited by 24
Self-citationHER-2/neu overexpression and in vitro chemosensitivity to CMF and FEC in primary breast cancer
Konecny, G. E., Fritz, M., Untch, M., Lebeau, A., Felber, M., Lude, S., Beryt, M., Hepp, H. K., Slamon, D., & Pegram, M. D. (2001) · Breast Cancer Research and Treatment · doi:10.1023/a:1012226006395 · Cited by 22
Cited by
Wolff, A. C., Hammond, M. E. H., Schwartz, J. N., Hagerty, K. L., Allred, D. C., Cote, R. J., Dowsett, M., Fitzgibbons, P. L., Hanna, W. M., Langer, A., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.2775 · Cited by 4,434
Liedtke, C., Mazouni, C., Hess, K. R., André, F., Tordai, A., Mejia, J. A., Symmans, W. F., Gonzalez-Angulo, A. M., Hennessy, B., Green, M., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.4147 · Cited by 2,892
Adjuvant Trastuzumab in HER2-Positive Breast Cancer
Slamon, D., Eiermann, W., Robert, N., Pienkowski, T., Martin, M., Press, M., Mackey, J., Glaspy, J., Chan, A., Pawlicki, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa0910383 · Cited by 2,775
Metastatic Behavior of Breast Cancer Subtypes
Kennecke, H., Yerushalmi, R., Woods, R., Cheang, M. C. U., Voduc, D., Speers, C. H., Nielsen, T. O., & Gelmon, K. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.9820 · Cited by 2,262
Harris, L., Fritsche, H., Mennel, R., Norton, L., Ravdin, P., Taube, S., Somerfield, M. R., Hayes, D. F., & Bast, R. C. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.2364 · Cited by 2,217
Metadata
- Authors
- Pritchard, K. I., Shepherd, L. E., O'Malley, F. P., Andrulis, I. L., Tu, D., Bramwell, V. H., & Levine, M. N.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2006-05-18
- Volume
- 354
- Issue
- 20
- Pages
- 2103-2111
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2078881615
- Cited by
- 509
- References
- 26
- FWCI
- 33.33
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.